We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Dipstick Technology Could Offer Faster, Cheaper and Mobile COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 07 Oct 2020
A new technology that helps to quickly extract and analyze genetic material could be used for cheap, accurate and mobile COVID-19 testing, including at airports and remote testing centers.

‘Dipstick’ technology, developed by the University of Queensland (Queensland, Australia) allows genetic material to be extracted in as little as 30 seconds, with a full molecular diagnosis in 40 minutes. More...
The process can be used to extract genetic material from most living organisms, including people, livestock, bacteria and viruses. The researchers have already applied the technology in other areas, primarily to fight plant pathogens. According to the team, their dipsticks can be produced quickly, cheaply and in bulk using a household pasta maker.

“Our dipstick tech is incredibly cheap and can be used virtually anywhere, without the need for specialized equipment or a laboratory,” said Professor Jimmy Botella of the University of Queensland. “Our tech enables the purification of DNA and RNA nucleic acids from patient samples - a critical step in COVID-19 diagnosis.”

“Combined with a portable diagnostic machine we’ve developed - which fits in your hand and can be powered by a car’s cigarette lighter connection - we could enable faster identification and isolation of positive patients, helping to reduce the spread of the disease,” added Botella. “We’re hoping it will be used to expand COVID-19 diagnostic testing to non-laboratory environments such as airports, remote testing centers and GP clinics.”

Related Links:
University of Queensland


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.